Xandr Universal Pixel

iHealth® Rapid Antigen 2-Test Pack

iHealth Labs
SKU: RD1-c

$10.50

Helps Individuals who want to take ownership of their health by providing the latest screening available against Covid-19 and its variants and want to know how healthy they really are because unlike any other Clinical Diagnostics marketplace we offer convenient, unfettered access to validated tests.  

In stock

Helps Individuals who want to take ownership of their health by providing the latest screening available against Covid-19 and its variants and want to know how healthy they really are because unlike any other Clinical Diagnostics marketplace we offer convenient, unfettered access to validated tests.  

The Fine Print

 

COVID-19 antigen test with rapid results in 15 minutes, and app with administrative results portal.

Suitable for home use or business and event screening.

The test can be completed in the comfort of your own home without the need to ship your sample to a lab.

Two Easy four-step tests

Noninvasive & highly absorbent nasal swab

Compact size for ease in traveling

FDA authorized under an Emergency Use Authorization (EUA)

The iHealth ® COVID-19 Antigen RapidTest is authorized for non-prescription home use with:

  • Adult collected anterior nasal (nares) swab samples 
  • Individuals aged 2 years or older with symptoms of COVID-19 within the first 7 days of symptoms (Age 2-15 requires an adult to collect the sample).  
  • Reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests

A negative result does not rule out COVID-19 and should not be used as the sole basis for treatment/management decisions. In symptomatic patients, specimens collected after day 5 of illness may be more likely to be negative compared to a RT-PCR assay. Negative results should be treated as presumptive and confirmed with a molecular assay, if necessary, for patient management.
When do I need to test again (serial testing)?

A negative test result does not rule out infection but repeat testing over two or three days may decrease the risk of false negative results. An initial negative test result should be the first of a minimum of two tests. An asymptomatic individual undergoing serial testing with two or more negative results may require ongoing serial testing or confirmatory testing, depending on patient history and potential exposures. An asymptomatic individual undergoing serial testing with one or more positive results indicates that SARS-CoV-2 antigen is present, but does not rule out infection with other pathogens.

What is an EUA?

What is an EUA? The United States FDA has made this test available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service’s (HHS’s) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19. An IVD made available under an EUA has not undergone the same type of review as an FDA-approved or cleared IVD. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, available alternatives, and based on the totality of scientific evidence available, it is reasonable to believe that this IVD may be effective in diagnosing COVID-19.

Nasal swab

  • No products in the cart.